Download Full eBooks in PDF
Progress Of Translational Medicine In Alzheimer S Disease Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Progress Of Translational Medicine In Alzheimer S Disease book. This book definitely worth reading, it is an incredibly well-written.
Author : Can Martin Zhang,Changning Wang,Evandro Fei Fang
Publisher : Frontiers Media SA
Page : 216 pages
File Size : 48,6 Mb
Release : 2022-08-04
Category : Science
ISBN : 9782889767120
Author : RICHARD A. SMITH
Publisher : Elsevier
Page : 518 pages
File Size : 47,6 Mb
Release : 2021
Category : Electronic
ISBN : 9780323907262
Author : Barry Leonard
Publisher : DIANE Publishing
Page : 64 pages
File Size : 53,6 Mb
Release : 2011-05
Category : Health & Fitness
ISBN : 9781437944808
The U.S. investment in Alzheimer¿s research through the Nat. Inst. of Health (NIH) has resulted in accelerating progress on several research fronts and laid the groundwork for future discovery. This report highlights key findings related to: discovery of new genes and biological mechanisms that cause Alzheimer¿s disease; earlier disease detection using neuro-imaging and biomarkers; links between Alzheimer¿s and other age-related diseases; rapid translation of lab findings to potential treatments; lifestyle factors that may protect against the disease; successful cognitive aging; clinical trials underway now to prevent or treat Alzheimer¿s and cognitive decline; research-tested strategies to support caregivers. Illus. This is a print on demand report.
Author : Aamir Shahzad
Publisher : Academic Press
Page : 196 pages
File Size : 46,8 Mb
Release : 2015-11-24
Category : Medical
ISBN : 9780128034941
Translational Medicine: Tools and Techniques provides a standardized path from basic research to the clinic and brings together various policy and practice issues to simplify the broad interdisciplinary field. With discussions from academic and industry leaders at international institutions who have successfully implemented translational medicine techniques and tools in various settings, readers will be guided through implementation strategies relevant to their own needs and institutions. The book also addresses regulatory processes in USA, EU, Japan and China. By providing details on omics sciences techniques, biomarkers, data mining and management approaches, case reports from industry, and tools to assess the value of different technologies and techniques, this book is the first to provide a user-friendly go-to guide for key opinion leaders (KOLs), industry administrators, faculty members, clinicians, researchers, and students interested in translational medicine. Includes detailed and standardized information about the techniques and tools used in translational medicine Provides specific industry case scenarios Explains how to use translational medicine tools and techniques to plan and improve infrastructures and capabilities while reducing cost and optimizing resources
Author : Michael S. Wolfe
Publisher : Academic Press
Page : 676 pages
File Size : 40,8 Mb
Release : 2016-05-27
Category : Medical
ISBN : 9780128021644
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches
Author : Anonim
Publisher : Unknown
Page : 342 pages
File Size : 46,6 Mb
Release : 2000
Category : Alzheimer's disease
ISBN : UCBK:C095493481
Author : George G. Nomikos,Douglas E. Feltner
Publisher : Academic Press
Page : 458 pages
File Size : 40,8 Mb
Release : 2019-06-18
Category : Medical
ISBN : 9780128031643
Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans. Includes comprehensive coverage of biomarker tools and the role of personalized medicine in CNS drug development Discusses strategies for drug development for a full range of CNS indications, with particular attention to neuropsychiatric and neurocognitive disorders Includes chapters written by international experts from industry and academia
Author : Abraham Fisher,Israel Hanin,Mitsuo Yoshinda
Publisher : Springer Science & Business Media
Page : 846 pages
File Size : 42,8 Mb
Release : 2012-12-06
Category : Medical
ISBN : 9781461553373
This book represents the fourth ina series of international conferences related to Alzheimer's (AD) and Parkinson's (PO) diseases. The first one took place in EHat, Israel in 1985; the second in Kyoto, Japan, in 1989; and the third in Chicago, IL, USA in 1993. This book incorporates the proceedings of the Fourth International Conference on Pro gress in Alzheimer's and Parkinson's Diseases, held in EHat, Israel, on May 18-23, 1997. This Conference was the 41st in the series of annual OHOLO Conferences sponsored by the Israel Institute for Biological Research (IIBR). It was also conducted under the aus pices of the Alzheimer's Association Ronald and Nancy Reagan Research Institute, USA. The Conference was attended by 550 participants from 28 countries, representing a broad spectrum of research interests; and included a well-balanced representation from aca demia, clinical institutions and pharmaceutical industry. The four-and-one-half day meeting served as an excellent medium for surveying the current preclinical and clinical develop ments in AD, PO, and other related disorders. The scientific program was divided into 24 oral sessions and daily poster sessions. The conference culminated in a round table discus sion. There were 122 talks and 161 posters. This book incorporates a combination of both.
Author : Domenico Praticὸ,Patrizia Mecocci
Publisher : Springer Science & Business Media
Page : 236 pages
File Size : 48,6 Mb
Release : 2013-09-21
Category : Science
ISBN : 9781627035989
This volume systematically reviews the basic science and clinical knowledge of the role of free radicals and antioxidants, collectively known as “oxidative stress,” in the pathology of Alzheimer’s disease. It describes the most current diagnostic tools, laboratory methods and technology, and suggests ways of prevention and treatment to emphasize the concept of the bench-to-bedside approach. Studies on Alzheimer’s Disease provides thorough coverage of emerging technology and medical applications including discussions of biomarkers and antioxidants as therapeutic agents, and several more relevant aspects. In addition, this book promotes the concept of using biomarkers representative of oxidative stress reactions and free-radical damageand describes the effects of antioxidants in treating disease in clinical trials. This content is invaluable to both researchers and clinicians studying the development of and treating patients with Alzheimer’s Disease.
Author : Abraham Fisher,Maurizio Memo,Fabrizio Stocchi,Israel Hanin
Publisher : Springer Science & Business Media
Page : 497 pages
File Size : 45,7 Mb
Release : 2007-12-26
Category : Medical
ISBN : 9780387720760
This volume contains the proceedings of the 2005 ADPD conference and is unique in that it deals not only with issues related individually to Alzheimer’s disease and Parkinson’s disease, but also with the integration of these and other related diseases. The most up-to-date techniques and research findings are illustrated in this volume, which covering topics from immunology, neuroscience, and pharmacology to genetics and molecular biology. Possible future developments in the treatment of Alzheimer’s and Parkinson’s Diseases are also covered.
Author : Miao-Kun Sun
Publisher : Nova Publishers
Page : 452 pages
File Size : 50,7 Mb
Release : 2007
Category : Alzheimer's disease
ISBN : 1600219608
Alzheimer's disease (AD), the most common form of neurodegenerative disorder in the elderly, is characterised pathologically by extracellular amyloid plaques and intracellular neurofibrillary tangles, pathophysiologically by synaptic dysfunction, and clinically by a progressive decline in cognition. Currently, AD has no cure and its prevalence is predicted to triple by 2050 with the rapid increase in the ageing population, unless more effective treatments are developed. Since the publication of the second book volume, the rapid progress in the research fields of AD and dementia continues through the intensive efforts of research scientists worldwide. This third book volume contains 15 chapters, bringing together a presentation of research frontiers in current AD/dementia research. The topics include molecular genetics of AD, gene expression abnormalities in AD progression, presenilins, taupathy in AD, single -induced(neuron gene expression abnormalities in AD, intracellular A neurodegeneration, roles of lipoprotein receptors in AD onset and progression, cholesterol and tau hyperphosphorylation, AD diagnostics and therapeutic strategies, in vivo visualisation of amyloid-like structures, cathepsin B, antiamyloidogenesis and neuroprotection, environmental enrichment, Fragile X mental retardation gene and dementia, category learning in Parkinson's disease, cerebrovascular disease and dementia, and dementia and hypertension. These chapters cover current advances in our understanding of the pathogenic mechanisms underlying AD and dementia, in the diagnosis of early AD and dementia, and in the development of therapeutic agents that target memory-relevant AD pathogenesis. The book will be highly valuable to students and scientists worldwide who are interested in the scientific research progress in AD and dementia.
Author : National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publisher : National Academies Press
Page : 47 pages
File Size : 54,9 Mb
Release : 2016-02-26
Category : Medical
ISBN : 9780309379755
Health information technology is providing patients, clinicians, and researchers with access to data that will enable novel approaches to science and medicine. Digital health records (DHRs) are capable of being shared across different health care settings for the examination of possible trends and long-term changes in a patient's disease progression or status as well as the effectiveness of the health care delivery system. While prevalence of paper records remains high, there has been a rapid trend toward the digitalization of medical and health records in many countries. DHRs are widely viewed as essential for improving health, reducing medical errors, and lowering costs. However, given that these databases have the potential to house the complete medical and health information of individuals, the potential misuse, de-identification or breaching of this data may have serious implications. On July 20, 2015, the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a public session at the 2015 Alzheimer's Association International Conference to assess the impact of DHRs on Alzheimer's disease (AD) research. An estimated 46.8 million people worldwide are currently living with dementia, and the prevalence is expected to double every year for the next 20 years. Given the few therapies currently available to treat the symptoms of AD, compared to other central nervous system disorders, participants explored how DHRs may be used to help improve clinical trial design and methodology for AD research. This report summarizes the presentations and discussions from this workshop.
Author : Samuel Barrack
Publisher : iMedPub
Page : 117 pages
File Size : 44,7 Mb
Release : 2012-01-30
Category : Medical
ISBN : 9781475095425
Alzheimer's disease (AD), is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. The cause and progression of Alzheimer's disease are not well understood. Research indicates that the disease is associated with plaques and tangles in the brain. Current treatments only help with the symptoms of the disease. There are no available treatments that stop or reverse the progression of the disease. As of 2012, more than 1000 clinical trials have been or are being conducted to find ways to treat the disease, but it is unknown if any of the tested treatments will work. Because AD cannot be cured and is degenerative, the sufferer relies on others for assistance. The role of the main caregiver is often taken by the spouse or a close relative. Alzheimer's disease is known for placing a great burden on caregivers; the pressures can be wide-ranging, involving social, psychological, physical, and economic elements of the caregiver's life. In developed countries, AD is one of the most costly diseases to society. Research is the only hope to present and future patients and families suffering from this devastating disorder. This book compiles some of the most interesting articles on Alzheimer's disease published by PLoS journals lately: from epidemiology and prevention to management and treatment.
Author : Suzanne Corkin
Publisher : Unknown
Page : 560 pages
File Size : 51,8 Mb
Release : 1982
Category : Medical
ISBN : UOM:39015045484246
Author : Robert Becker,Ezio Giacobini
Publisher : Springer Science & Business Media
Page : 636 pages
File Size : 51,5 Mb
Release : 1996-12-01
Category : Medical
ISBN : 0817638792
This volume reviews the new potential treatments and research in the area of Alzheimer's disease. Special attention is given to international developments in all fields relevant to new drug development. Topics discussed include: progress in the international harmonization of drug development guidelines for dementia drugs; bioethics and law; development of rating instruments; behavioural treatments; and the activities of the Reagan Foundation. The text integrates basic and clinical research findings, and provides evaluation of new approaches to therapy by world leaders in the field. The potential benefit for Alzheimer patients and families resulting from these research programmes, from molecular biology to clinical pharmacology, is reviewed and evaluated.
